Skip to main content
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. — Investor Relations & Filings

Ticker · CTKB ISIN · US23285D1090 LEI · 549300K2J28BOC6FBO89 US Manufacturing
Filings indexed 412 across all filing types
Latest filing 2026-06-02 Board/Management Inform…
Country US United States of America
Listing US CTKB

About Cytek Biosciences, Inc.

https://cytekbio.com

Cytek Biosciences, Inc. is a cell analysis solutions company that provides instruments, reagents, and services based on its patented Full Spectrum Profiling (FSP) technology. This technology enables its flow cytometry systems, including the Aurora, Northern Lights, and Muse series, to capture the entire emission spectrum of fluorescent dyes. This allows researchers to conduct high-resolution, high-multiplex experiments, using panels of 40 or more colors from a single sample. By providing more data from precious samples, the technology aims to reduce experimental complexity and cost. Cytek offers a complete solution with its cFluor® reagents, which are optimized for spectral cytometry, alongside software and application support. The company's products are intended to advance biomedical research in fields such as immunology, cancer research, and cell biology.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 92% confidence The document is a SEC Form 8-K current report by Cytek Biosciences, specifically Item 5.02 concerning the resignation of a senior officer (Senior Vice President, Global Sales and Services). This is an announcement of a change in senior management, which falls under Board/Management Information.
2026-06-02 English
SD
Regulatory Filings Classification · 91% confidence The document is filed on SEC Form SD (“Specialized Disclosure Report”) under Rule 13p-1 for conflict minerals disclosure. It is a regulatory compliance filing and does not contain financial statements, management discussion, or market presentations. There is no specific category for Form SD conflict minerals reports, so it falls under the general Regulatory Filings category (RNS).
2026-06-01 English
10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
ARS - Cytek Biosciences, Inc. (0001831915) (Filer)
Annual Report
2026-04-28 English
10-K - CYTEK BIOSCIENCES, INC. (0001831915) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - CYTEK BIOSCIENCES, INC. (0001831915) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 26, 2026, reporting the issuance of a press release announcing financial results for the quarter and full year ended December 31, 2025. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document is short (3339 characters) and primarily serves to announce the release of financial results rather than containing the results themselves. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is Earnings Release (ER).
2026-02-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.